Answers are grounded in this paper and cite their sources.
Investigates empagliflozin's impact on ferroptosis in myocardial infarction, suggesting a protective mechanism.
Emerging evidence implicates ferroptosis in myocardial ischemic injury. This study aimed to investigate whether empagliflozin (EMP) suppresses ferroptosis in acute myocardial infarction (AMI) via the AMP-activated protein kinase (AMPK)/nuclear factor erythroid 2-related factor 2 (NRF2)/solute carrier family 7 member 11 (SLC7A11) pathway.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: